Clinical Trial: NCT04649359
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Pfizer |
| Information Provided By: | Pfizer |
| Last Update Posted: | 2026-10-19 |
Study Overview
Brief Summary
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Official Title
MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
Conditions
Multiple Myeloma
Intervention / Treatment
- Drug: Elranatamab (PF-06863135)
Other Study ID Numbers
- C1071003
- MagnetisMM-3
- 2023-504479-25-00
- 2023
Start Date (Actual)
2021-02-02
Primary Completion Date (Actual)
2022-06-17
Study Completion Date (Actual)
2026-08-25
Enrollment (Actual)
187
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Pfizer |
| Information Provided By: | Pfizer |
| Last Update Posted: | 2026-10-19 |
Study Overview
Brief Summary
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Official Title
MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
Conditions
Multiple Myeloma
Intervention / Treatment
- Drug: Elranatamab (PF-06863135)
Other Study ID Numbers
- C1071003
- MagnetisMM-3
- 2023-504479-25-00
- 2023
Start Date (Actual)
2021-02-02
Primary Completion Date (Actual)
2022-06-17
Study Completion Date (Actual)
2026-08-25
Enrollment (Actual)
187
Study Type
Interventional
Phase
Phase 2